Nansha company's sodium bromfenac eye drops approved for market

Ocusun Runer Ophthalmic Biotechnology Company, a biopharmaceutical company in Nansha district, recently introduced its first product - sodium bromfenac eye drops, which have been approved for the market.

Ocusun Runer Ophthalmic Biotechnology Company. [Photo/WeChat account: gz_nanshafabu]

This eye medication marks the company's first drug approval and is designed to treat inflammatory diseases of the external and anterior parts of the eye, such as blepharitis, conjunctivitis, and postoperative inflammation.

Runer Ophthalmic Biotechnology Company is a high-tech innovative enterprise dedicated to global drug research and development, possessing a proprietary global drug design platform and innovative drug formulation technology. The company was recognized as one of the top 10 innovative forces in China's pharmaceutical industry in 2023.

In addition to sodium bromfenac eye drops, the company has several innovative drugs in various stages of development, including the groundbreaking first-in-class cataract eye drops with significant clinical and economic value.

Nansha is home to over 400 biopharmaceutical companies, signaling a new phase of development in the biopharmaceutical industry.